REVERT-IPF: A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis.
Latest Information Update: 30 May 2025
At a glance
- Drugs TTI 101 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Acronyms REVERT-IPF
- Sponsors Tvardi Therapeutics
Most Recent Events
- 27 May 2025 According to a Tvardi Therapeutics media release, the company has completed enrollment for its lead program in a Phase 2 clinical trial of TTI-101 for patients with idiopathic pulmonary fibrosis (IPF).Topline data from the REVERT IPF trial anticipated in 4Q 2025.
- 27 May 2025 Status changed from recruiting to active, no longer recruiting, according to a Tvardi Therapeutics media release.
- 22 May 2025 Planned End Date changed from 17 Jul 2025 to 25 Aug 2025.